Suat Bilici, Deniz Tuna Edizer, Ozgur Yigit, Muhammet Yildiz, Tevfik Fikret Cermik
Otorhinolaryngology Department, Istanbul Training and Research Hospital, Istanbul, Turkey.
Am J Rhinol Allergy. 2016 Nov 1;30(6):206-210. doi: 10.2500/ajra.2016.30.4384.
To determine the possible adverse effects of radioactive iodine (RAI) treatment on the olfactory functions of patients with differentiated thyroid carcinoma.
This prospective clinical study included 63 Turkish patients who had been diagnosed with papillary thyroid carcinoma only to ensure homogeneity. The Connecticut Chemosensory Clinical Research Center olfactory test was administered at 1 week before treatment and at the third week and the first year after treatment. Triiodothyronine, thyroxine, thyroid stimulating hormone, thyroglobulin, and antithyroglobulin levels were measured 1 week before treatment and 2 weeks after treatment.
The smell threshold test, smell identification test, and total smell scores showed statistically significant decreases after treatment when compared with the pretreatment scores (p = 0.000). No significant differences were noted between the late term and early term after RAI for either the identification score (p = 0.502) or the total score (p = 0.051). The Spearman correlation analysis indicated a significant correlation between age and RAI before and after treatment for the smell threshold test, smell identification test, and total smell scores (p < 0.05). A total of 54% of the patients displayed normosmia in the posttreatment period. A few patients had mild hyposmia before RAI, 27% had mild hyposmia in the early stage after RAI, and 29% had mild hyposmia in the late stage.
The olfactory function deteriorated in almost half of the patients in the early stage after RAI. Mild and moderate hyposmia in particular occurred in the first year after RAI.
确定放射性碘(RAI)治疗对分化型甲状腺癌患者嗅觉功能的可能不良影响。
这项前瞻性临床研究纳入了63例仅被诊断为乳头状甲状腺癌的土耳其患者,以确保同质性。在治疗前1周、治疗后第3周和第1年进行康涅狄格化学感觉临床研究中心嗅觉测试。在治疗前1周和治疗后2周测量三碘甲状腺原氨酸、甲状腺素、促甲状腺激素、甲状腺球蛋白和抗甲状腺球蛋白水平。
与治疗前评分相比,治疗后嗅觉阈值测试、嗅觉识别测试和总嗅觉评分显示出统计学上的显著下降(p = 0.000)。RAI治疗后晚期与早期相比,识别评分(p = 0.502)或总分(p = 0.051)均无显著差异。Spearman相关性分析表明,年龄与治疗前后RAI的嗅觉阈值测试、嗅觉识别测试和总嗅觉评分之间存在显著相关性(p < 0.05)。共有54%的患者在治疗后阶段嗅觉正常。少数患者在RAI治疗前有轻度嗅觉减退,27%在RAI治疗后的早期有轻度嗅觉减退,29%在晚期有轻度嗅觉减退。
RAI治疗后早期几乎一半的患者嗅觉功能恶化。尤其是在RAI治疗后的第一年出现了轻度和中度嗅觉减退。